Back to today’s briefing

Story perspectives

FDA Abolishes Clozapine REMS, Boosting Schizophrenia Treatment Access

2/26/2025

34 3

Summary

FDA Abolishes Clozapine Restrictions

In a groundbreaking move, the FDA has decided to abolish the clozapine REMS program, a decision influenced by experts who highlighted its role in restricting access to this vital schizophrenia treatment. While ANC monitoring will still be advised, this change promises to enhance patient access and alleviate healthcare challenges for those battling treatment-resistant schizophrenia in the U.S.

Summary

Teva Advances Mental Health

Teva Pharmaceuticals is making strides in mental health treatment with its supplemental New Drug Application for Uzedy, an extended-release injectable designed for bipolar I disorder, building on its recent schizophrenia approval. In a parallel breakthrough, Adial Pharmaceuticals has secured FDA approval for its innovative in vitro strategy for AD04, aimed at combating addiction.

1 of 2

FDA Abolishes Clozapine Restrictions

In a groundbreaking move, the FDA has decided to abolish the clozapine REMS program, a decision influenced by experts who highlighted its role in restricting access to this vital schizophrenia treatment. While ANC monitoring will still be advised, this change promises to enhance patient access and alleviate healthcare challenges for those battling treatment-resistant schizophrenia in the U.S.

1 / 2